Log In

Seventeen years of statin pharmacogenetics: a systematic review

Files

pgs.15.pdf (1.41 MB)
How and where to find an Open Access version of this publication?

Publication date

2016

Authors

Leusink, Maarten
Onland-Moret, N. CharlotteORCID 0000-0002-2360-913XISNI 0000000392818805
de Bakker, Paul I.W.
de Boer, Anthonius
Maitland-van der Zee, Anke H

Editors

Advisors

Supervisors

DOI

https://doi.org/10.2217/pgs.15.158

Document Type

Article

Metadata

Show full item record

Collections

UMC Repository

License

Abstract

AIM: We evaluated the evidence of pharmacogenetic associations with statins in a systematic review. METHODS: Two separate outcomes were considered of interest: modification of low-density lipoprotein cholesterol (LDL-C) response and modification of risk for cardiovascular events. RESULTS: In candidate gene studies, 141 loci were claimed to be associated with LDL-C response. Only 5% of these associations were positively replicated. In addition, six genome-wide association studies of LDL-C response identified common SNPs in APOE, LPA, SLCO1B1, SORT1 and ABCG2 at genome-wide significance. None of the investigated SNPs consistently affected the risk reduction for cardiovascular events. CONCLUSION: Only five genetic loci were consistently associated with LDL-C response. However, as effect sizes are modest, there is no evidence for the value of genetic testing in clinical practice.

Keywords

candidate gene studies, genome-wide association studies, LDL cholesterol, pharmacogenetics, review, statins, Journal Article, Review

Citation

Leusink, M, Onland-Moret, N C, de Bakker, P, de Boer, A & Maitland-van der Zee, A H 2016, 'Seventeen years of statin pharmacogenetics : a systematic review', Pharmacogenomics, vol. 17, no. 2, pp. 163-180. https://doi.org/10.2217/pgs.15.158

URI

http://hdl.handle.net/1874/332752